Assessment of Serum Tumor Necrosis Factor-alpha (TNF-α) Levels in Type 2 Diabetes Mellitus Patients

Abstract Background: Type 2 diabetes mellitus (T2DM) is a chronic metabolic disorder characterized by persistent hyperglycemia, resulting from insulin resistance and pancreatic beta-cell dysfunction. Tumor necrosis factor-alpha (TNF-α), a pro-inflammatory cytokine, has been linked to insulin resistance and to the mechanisms underlying diabetic complications. This study aimed to compare serum TNF-α levels between patients with T2DM and healthy controls, and to examine their relationship with random blood glucose (RBG), age, body mass index (BMI), reported diabetic complications, infections, and clinical symptoms. Methods: In this case–control study (January–March 2026, Diyala, Iraq), 40 male patients with T2DM (ADA criteria; aged 19–73 years) were compared with 40 apparently healthy male controls (aged 20–55 years). Smokers, users of tobacco products, participants with chronic inflammatory diseases, and those receiving immunosuppressive therapy were excluded. Serum TNF-α was measured by ELISA. Group differences were tested with non-parametric tests (data were non-normal) and by ANCOVA on log-transformed TNF-α adjusted for age and body mass index (BMI). Written informed consent was obtained from all participants. tests (Mann–Whitney U, Kruskal–Wallis, and Spearman’s correlation) were used. Results: Median (IQR) serum TNF-α was significantly higher in patients than in controls (59.66 [45.10] vs. 29.53 [16.28] pg/mL; P < 0.001). The difference remained significant after adjustment for age (adjusted geometric means 63.4 vs. 29.4 pg/mL; P < 0.001) and for age and BMI (P < 0.001). Among patients, TNF-α was not significantly correlated with RBG (rs = 0.264, P = 0.100), age, or BMI, and did not differ significantly according to reported complications, infections, or symptoms (all P > 0.05). Conclusion: Serum TNF-α was higher in male patients with T2DM than in male controls, independent of age and BMI, supporting a link between T2DM and systemic inflammation. However, the groups were not age-matched, the sample was small, and complications were self-reported, so the findings should be interpreted cautiously and confirmed in larger, age-matched studies.

Authors

Publication Details

Journal
Zenodo (CERN European Organization for Nuclear Research)
Published
2026-10-14
DOI
https://doi.org/10.5281/zenodo.23363023
Primary Topic
Adipokines, Inflammation, and Metabolic Diseases
Type
article
Field-Weighted Citation Impact
0.00
Controls
|||
ALL TIME
JAN
FEB
MAR
APR
MAY
JUN
JUL
AUG
SEP
OCT
article

Assessment of Serum Tumor Necrosis Factor-alpha (TNF-α) Levels in Type 2 Diabetes Mellitus Patients

Ali Al-Bawatti
Zenodo (CERN European Organization for Nuclear Research)
Adipokines, Inflammation, and Metabolic Diseases
article

Assessment of Serum Tumor Necrosis Factor-alpha (TNF-α) Levels in Type 2 Diabetes Mellitus Patients

Ali Al-Bawatti
article en

Abstract

Abstract Background: Type 2 diabetes mellitus (T2DM) is a chronic metabolic disorder characterized by persistent hyperglycemia, resulting from insulin resistance and pancreatic beta-cell dysfunction. Tumor necrosis factor-alpha (TNF-α), a pro-inflammatory cytokine, has been linked to insulin resistance and to the mechanisms underlying diabetic complications. This study aimed to compare serum TNF-α levels between patients with T2DM and healthy controls, and to examine their relationship with random blood glucose (RBG), age, body mass index (BMI), reported diabetic complications, infections, and clinical symptoms. Methods: In this case–control study (January–March 2026, Diyala, Iraq), 40 male patients with T2DM (ADA criteria; aged 19–73 years) were compared with 40 apparently healthy male controls (aged 20–55 years). Smokers, users of tobacco products, participants with chronic inflammatory diseases, and those receiving immunosuppressive therapy were excluded. Serum TNF-α was measured by ELISA. Group differences were tested with non-parametric tests (data were non-normal) and by ANCOVA on log-transformed TNF-α adjusted for age and body mass index (BMI). Written informed consent was obtained from all participants. tests (Mann–Whitney U, Kruskal–Wallis, and Spearman’s correlation) were used. Results: Median (IQR) serum TNF-α was significantly higher in patients than in controls (59.66 [45.10] vs. 29.53 [16.28] pg/mL; P < 0.001). The difference remained significant after adjustment for age (adjusted geometric means 63.4 vs. 29.4 pg/mL; P < 0.001) and for age and BMI (P < 0.001). Among patients, TNF-α was not significantly correlated with RBG (rs = 0.264, P = 0.100), age, or BMI, and did not differ significantly according to reported complications, infections, or symptoms (all P > 0.05). Conclusion: Serum TNF-α was higher in male patients with T2DM than in male controls, independent of age and BMI, supporting a link between T2DM and systemic inflammation. However, the groups were not age-matched, the sample was small, and complications were self-reported, so the findings should be interpreted cautiously and confirmed in larger, age-matched studies.

Zenodo (CERN European Organization for Nuclear Research)
Good health and well-being
Openalex Percentile: Top 13%
Adipokines, Inflammation, and Metabolic Diseases
AI Navigator

Ask Laika to Summarize, Analyze, and Connect papers live on the map.

Summarize Papers & Methodologies

Extract key findings, datasets, and comparative methods across publications.

Benchmark Rankings & Visual Analytics

Rank top research institutions, authors, funders, topics, and journals by Field-Weighted Citation Impact (FWCI) and paper volume with instant charts.

Connect Distant Disciplines

Bridge topological clusters on the map to find hidden collaborative intersections.